NATX Plasmids, for: DNA Vaccines, Gene Therapeutics, Viral Vectors andBiophamacueticals

Full Circle Pharmacuetical Development: Vector, Strain, Process and Product Development

NTC Contacts:
Phone: (402) 323-6289 (natx)
Fax: (402) 323-6292
Email: support@natx.com

site map | home | contact us
NTC PRODUCTS AND SERVICES

MAMMALIAN EXPRESSION VECTORS
X• Antibiotic-Free Vectors
X• Rig-I Activating Vectors
X• Linear Vectors
X• Recombineering Vectors
X• Gene Silencing (transient)
X• Gene Silencing (retroviral, stable)
X• Anti-Silencing Elements
X• Vector Pricing

CELL LINES
X• Autolytic E. coli Cell Lines
X• dcm- Strains

VACCINES & ADJUVANTS
X• DNA Vaccines
X• Rig-I Activating DNA Vaccines
X• Thermostable Protein Expression

PRECISION CLONING
X• Services and Pricing

RECOMBINANT PROTEINS
X• pVEX™-E. coli Expression Vectors
X• Fluorescent Proteins
X• Products, Vectors, Services, Prices
X• CofA (SAMPLE)

PLASMIDS
X• Small Scale Plasmid DNA
X• Small Scale C of A
X• Large Scale Plasmid DNA
X• Large Scale C of A
X• Plasmid DNA Order Form
X• E. coli Cell paste
X• NEW! Plasmid Detox Service
X• Additional Testing

PROCESS DEVELOPMENT

DNA FERMENTATION PROCESS
X• HyperGRO™ Publications
X• E. coli Cell Paste

HYPERTAQ™ DNA POLYMERASE

CONTRACT QC
X• E. coli Genomic DNA Testing
X• Residual RNA qPCR
X• Residual RNA gel
X• Supercoil Assay
X• Lymulus Endotoxin Testing

Biologics are rapidly replacing small molecule drugs. In addition to recombinant proteins, monoclonal antibodies and peptide hormones, next generation biotechnology products include DNA vaccines and plasmid gene therapeutics. Unlike their predecessors, gene-based drugs are designed from the ground up, starting with an optimized vector and rationally designed genes.

NTC Vector Development: From Concept to Reality

•     State of the art facilities

•     Expert staff

•     Rapid construction

•     Precision, single-base construction using GENSA™ technology
Vector development is the initial and rate limiting factor in biologics development

NTC genetic designers create rationally designed components for maximal expression. An optimized NTC backbone vector is the starting point for precision cloning, completed in days.

[Case study: NTC’s pDNAVACCUltra DNA vaccination platform.] Ref: Williams et al., 2009, Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream production
Carnes et al., Autolysis strains

Strain Development: Living Cell Factories for Biopharmaceutical Production

Specialized biological products require specialized cells or organisms for their production.  NTC has devised Genome Mass Transfer (GMTtm) technology for rapid, precise alteration of microbial genomes.  NTC’s bacterial host strains are made rapidly and precisely in response to the need for specialized functions: autolysis purification; nucleases for clearance of host genomic DNA and RNA; or antisense RNAs for control over copy number or plasmid selection.

[Case study: NTC’s autolytic processing host strains.] Ref: Williams et al., 2009 Strain engineering by genome mass transfer: efficient chromosomal trait transfer method utilizing donor genomic DNA and recipient recombineering hosts

Process Development: Designing the Most Effective Methods of Production

BioProcess development is aimed at the most efficient production of complex biological molecules in two stages: upstream fermentation and downstream purification. 

[Case study: NTC’s HyperGRO™ process for plasmid DNA fermentation.] Ref: Carnes et al., 2009 Plasmid DNA production combining antibiotic-free selection, inducible high yield fermentation, and novel autolytic purification.
Fed-batch HyperGRO fermentation proces

 Fluorescent proteins in E. coli

Product Development: New Age Therapeutics Designed to Fit

Biopharmaceutical products are rationally designed drugs, specialized with precision to meet important biochemical and biophysical criteria and target specificity.  Bioproducts represent the sum total of efforts in concept, design, and execution. NTC scientists provide a success-driven roadmap for product development, aimed at later stage successes in the clinic and marketplace. [Case study: NTC’s fluorescent proteins for flow cytometry labeling.]